Anti-Thy1.1 transgenic mice develop glomerular lesions that mimic collapsing focal segmental glomerulosclerosis (fSGS) in humans with collapse of the glomerular tuft and marked hyperplasia of the parietal epithelial cells (PECs). Immunostaining of phosphor-S6 ribosomal protein (pS6RP) revealed high mtoR activity in pecs of the fSGS lesions of these mice. in this study we questioned whether the mtoR inhibitor rapamycin (sirolimus) could attenuate the development and progression of glomerulosclerotic lesions in the anti-Thy1.1 transgenic mice. We observed reduced mTOR signalling and proliferation in human parietal epithelial cells after rapamycin treatment. experiments with anti-Thy1.1. mice showed that early treatment with sirolimus reduced the development of glomerular lesions and glomerular cell proliferation at day 4. Levels of albuminuria, podocyte injury and podocyte number were similar in the sirolimus and vehicle treated groups. The initial beneficial effects of sirolimus treatment were not observed at day 7. Late sirolimus treatment did not reduce albuminuria or the progression of glomerulosclerosis. taken together, rapamycin attenuated pec proliferation and the formation of early fSGS lesions in experimental fSGS and reduced human pec proliferation in vitro. However, the initial inhibition of pec proliferation did not translate into a decline of albuminuria nor in a sustained reduction in sclerotic lesions. Focal segmental glomerulosclerosis (FSGS) is characterized by the formation of sclerotic lesions in the glomeruli of the kidneys. FSGS is one of the most common glomerular disorders and the leading cause of end-stage renal disease (ESRD) in the United States 1. Several underlying conditions can lead to FSGS such as diabetes, hypertension and obesity. In addition, FSGS can be caused by genetic mutations affecting the function of essential glomerular cell proteins or it can be idiopathic 1,2. The diagnosis of FSGS is largely based on histopathological findings characterized by the adhesions of the Bowman's capsule with the glomerular tuft, the formation of focal and segmental sclerotic lesions, obliteration of glomerular capillaries and extracellular matrix accumulation 3,4. Currently, the different histological patterns of FSGS have been divided into five subvariants: the perihilar-, the tip-, the cellular-, the NOS (not otherwise specified)-, and the collapsing variant, latter is characterized by collapse of the glomerular tuft and PEC hyperplasia 2. The pathogenesis of FSGS is not completely unravelled. In the last decade we and others demonstrated that parietal epithelial cells (PECs) are crucially involved in the formation of sclerotic lesions. Genetic tagging of